Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SGEN

Seagen Inc

Dec 08 • 04:00PM ET

218.98

Dollar change +0.65
Percentage change 0.30	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	NDX	P/E	-	EPS (ttm)	-4.01	Insider Own	1.15%	Shs Outstand	186.56M	Perf Week	2.94%
Market Cap	41.31B	Forward P/E	-	EPS next Y	-1.85	Insider Trans	-2.13%	Shs Float	186.49M	Perf Month	2.44%
Income	-750.23M	PEG	-	EPS next Q	-0.96	Inst Own	86.76%	Short Float / Ratio	5.47% / 7.40	Perf Quarter	5.21%
Sales	2.30B	P/S	17.96	EPS this Y	-26.21%	Inst Trans	-2.09%	Short Interest	10.20M	Perf Half Y	11.38%
Book/sh	13.52	P/B	16.20	EPS next Y	55.57%	ROA	-20.69%	Target Price	228.90	Perf Year	83.46%
Cash/sh	6.56	P/C	33.38	EPS next 5Y	-	ROE	-27.93%	52W Range	117.58 - 219.43	Perf YTD	70.40%
Dividend	-	P/FCF	-	EPS past 5Y	-30.39%	ROI	-28.16%	52W High	-0.21%	Beta	0.27
Dividend %	-	Quick Ratio	2.12	Sales past 5Y	42.02%	Gross Margin	74.65%	52W Low	86.24%	ATR	1.67
Employees	3256	Current Ratio	2.67	Sales Q/Q	27.11%	Oper. Margin	-34.37%	RSI (14)	69.15	Volatility	0.95% 0.73%
Optionable	Yes	Debt/Eq	0.05	EPS Q/Q	-11.08%	Profit Margin	-32.61%	Rel Volume	0.86	Prev Close	218.33
Shortable	Yes	LT Debt/Eq	0.04	Earnings	Nov 01 BMO	Payout	-	Avg Volume	1.38M	Price	218.98
Recom	2.60	SMA20	2.44%	SMA50	2.26%	SMA200	8.72%	Volume	1,181,583	Change	0.30%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-16-23	Upgrade	Raymond James	Outperform → Strong Buy	$155 → $175
Feb-16-23	Upgrade	Evercore ISI	In-line → Outperform	$140 → $175
Feb-06-23	Downgrade	SVB Securities	Outperform → Market Perform	$162 → $141
Nov-21-22	Initiated	Truist	Hold	$135
Oct-11-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$177 → $178
Jun-29-22	Initiated	Raymond James	Outperform	$220
Jun-24-22	Initiated	BMO Capital Markets	Market Perform	$169
Feb-10-22	Reiterated	Wolfe Research	Peer Perform	$195 → $146
Feb-10-22	Reiterated	SVB Leerink	Outperform	$179 → $155
Feb-10-22	Reiterated	RBC Capital Mkts	Sector Perform	$154 → $132
Feb-10-22	Reiterated	Piper Sandler	Neutral	$165 → $150
Feb-10-22	Reiterated	Needham	Buy	$200 → $180
Feb-10-22	Reiterated	Morgan Stanley	Overweight	$175 → $170
Feb-10-22	Reiterated	H.C. Wainwright	Buy	$200 → $170
Feb-10-22	Reiterated	BofA Securities	Buy	$210 → $170
Jan-31-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$178 → $175
Nov-09-21	Initiated	Wolfe Research	Peer Perform	$195
Oct-15-21	Resumed	BTIG Research	Neutral
May-17-21	Initiated	Evercore ISI	In-line
Mar-31-21	Initiated	Credit Suisse	Neutral	$145

Show Previous Ratings

Dec-06-23 08:15AM	TUKYSA (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (Business Wire)
Dec-01-23 11:32AM	Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report? (Zacks)
Nov-30-23 05:00PM	FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV (enfortumab vedotin-ejfv) with KEYTRUDA (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer (PR Newswire)
Nov-03-23 12:00PM	Seagen Highlights First Solid Tumor Data for an ADCETRIS (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting (Business Wire)
Nov-02-23 02:42PM	Analyst Report: Seagen Inc. (Morningstar Research)
01:00PM	Loading…
01:00PM	New Data for ADCETRIS (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate (Business Wire)
Nov-01-23 09:42AM	Seagen Inc (SGEN) Reports 33% Increase in 3Q23 Net Product Sales (GuruFocus.com)
09:30AM	Seattle Genetics (SGEN) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:09AM	Seattle Genetics: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress (Business Wire)
Oct-26-23 10:02AM	Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to Decline (Zacks)
Oct-25-23 10:02AM	Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-22-23 10:30AM	TIVDAK (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial (Business Wire)
10:30AM	Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV (enfortumab vedotin-ejfv) and KEYTRUDA (pembrolizumab) in First-Line Advanced Bladder Cancer (PR Newswire)
Oct-20-23 10:31AM	Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research (PR Newswire)
08:00AM	Loading…
Oct-16-23 08:00AM	Seagen to Highlight Overall Survival Data for PADCEV and TIVDAK during Presidential Symposium at ESMO Congress 2023 (Business Wire)
Oct-12-23 08:00AM	Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023 (Business Wire)
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Sep-24-23 12:05AM	The Hedge Fund That Made a Killing Betting Against Lina Khan (The Wall Street Journal)
Sep-22-23 02:35PM	Stocks to Watch Friday: Alibaba, Activision, Microsoft, Ford, Meta Platforms (The Wall Street Journal)
05:00AM	PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial (PR Newswire)
Sep-12-23 06:36AM	Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains? (Zacks)
Sep-07-23 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report? (Zacks)
Sep-06-23 08:00AM	Biden FTCs Antitrust Bark Proves Worse Than Its Bite (The Wall Street Journal)
Sep-04-23 03:00PM	Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone (Business Wire)
03:00PM	Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy (Business Wire)
Sep-01-23 11:31AM	Why Is Seattle Genetics (SGEN) Up 6.5% Since Last Earnings Report? (Zacks)
Aug-28-23 07:07PM	Analyst Report: Seagen Inc. (Morningstar Research)
Aug-16-23 08:00AM	Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (Business Wire)
Aug-03-23 01:04PM	Analyst Report: Seagen Inc. (Morningstar Research)
10:00AM	Loading…
Aug-02-23 10:00AM	Seattle Genetics (SGEN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:15AM	Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:04AM	Seattle Genetics: Q2 Earnings Snapshot (AP Finance)
08:00AM	Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum (Business Wire)
Jul-26-23 10:02AM	Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-12-23 08:00AM	Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023 (Business Wire)
Jul-06-23 04:43PM	Investors focus on how Pfizer will spend COVID-19 windfall: GS (Yahoo Finance Video)
Jul-04-23 12:45PM	Best Under-the-Radar Stocks: 3 That AI Predicts Will Soar in July (InvestorPlace)
Jun-20-23 08:30AM	Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma (Business Wire)
Jun-14-23 08:31PM	Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma (Business Wire)
Jun-13-23 03:01AM	Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL) (Business Wire)
Jun-07-23 09:57PM	Analyst Report: Seagen Inc. (Morningstar Research)
May-30-23 03:22PM	Seagen Stockholders Approve Acquisition by Pfizer (Business Wire)
May-25-23 08:00AM	We're Not Worried About Seagen's (NASDAQ:SGEN) Cash Burn (Simply Wall St.)
May-16-23 07:07PM	Analyst Report: Seagen Inc. (Morningstar Research) -5.97%
11:47AM	FTCs Amgen Activism Will Spare These Biotechs (The Wall Street Journal)
11:21AM	FTC sues to block Amgen's $28B acquisition of Horizon Therapeutics (Yahoo Finance)
09:00AM	Seagen (NASDAQ:SGEN) shareholders have earned a 29% CAGR over the last five years (Simply Wall St.)
May-12-23 09:00AM	Seagen Inc. (NASDAQ:SGEN) is largely controlled by institutional shareholders who own 65% of the company (Simply Wall St.)
May-08-23 09:00AM	Estimating The Intrinsic Value Of Seagen Inc. (NASDAQ:SGEN) (Simply Wall St.)
May-01-23 05:31PM	Analyst Report: Seagen Inc. (Morningstar Research)
Apr-29-23 09:00AM	16% of this Seagen Inc. (NASDAQ:SGEN) insider's holdings were sold in the last year (Simply Wall St.)
Apr-27-23 10:00AM	Seattle Genetics (SGEN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:15AM	Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Seagen Reports First Quarter 2023 Financial Results (Business Wire)
Apr-26-23 10:48AM	Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting (Business Wire)
Apr-25-23 10:01AM	Repligen (RGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-24-23 08:00AM	We're Interested To See How Seagen (NASDAQ:SGEN) Uses Its Cash Hoard To Grow (Simply Wall St.)
Apr-17-23 08:00AM	Seagen Inc.'s (NASDAQ:SGEN) Business Is Trailing The Industry But Its Shares Aren't (Simply Wall St.)
Apr-11-23 08:00AM	Investors in Seagen (NASDAQ:SGEN) have made a incredible return of 307% over the past five years (Simply Wall St.)
Apr-07-23 08:00AM	Seagen to Report First Quarter 2023 Financial Results on April 27, 2023 (Business Wire)
Apr-06-23 07:00AM	Estimating The Intrinsic Value Of Seagen Inc. (NASDAQ:SGEN) (Simply Wall St.)
Apr-03-23 05:00PM	FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (PR Newswire)
Mar-31-23 11:30AM	Amicus Therapeutics (FOLD) Down 14% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-30-23 11:30AM	Why Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report? (Zacks)
Mar-29-23 11:30AM	Axsome (AXSM) Down 9.8% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-27-23 08:00AM	A Seagen Inc. (NASDAQ:SGEN) insider lowered their holding by 16% earlier this year (Simply Wall St.)
Mar-24-23 11:30AM	Why Is Repligen (RGEN) Down 11.4% Since Last Earnings Report? (Zacks)
Mar-23-23 11:30AM	CRISPR Therapeutics AG (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound? (Zacks)
10:00AM	We're Not Worried About Seagen's (NASDAQ:SGEN) Cash Burn (Simply Wall St.)
Mar-17-23 07:11PM	First Republic Bank, T-Mobile, Credit Suisse: Stocks That Defined the Week (The Wall Street Journal)
11:30AM	Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report? (Zacks)
Mar-15-23 03:38PM	Medicare identifies drug makers that will owe penalties for raising prices on 27 drugs faster than rate of inflation (Yahoo Finance)
Mar-14-23 04:30PM	Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting (Business Wire)
04:53AM	Strength Seen in Seattle Genetics (SGEN): Can Its 14.5% Jump Turn into More Strength? (Zacks)
12:20AM	Analyst Report: Seagen Inc. (Morningstar Research)
12:01AM	Corrections & Amplifications (The Wall Street Journal)
Mar-13-23 03:06PM	Pfizer Agrees to Buy Seagen for $43 Billion (The Wall Street Journal) +14.51%
01:37PM	Pfizer Overpays for Seagen, but Whos Counting (The Wall Street Journal)
12:06PM	Pfizer to battle cancer with Seagen merger, CEO Albert Bourla says (Yahoo Finance Video)
10:19AM	Pfizer aiming to acquire Seagen in $43 billion deal (Yahoo Finance Video)
06:45AM	Pfizer Invests $43 Billion to Battle Cancer (Business Wire)
Mar-09-23 06:30PM	Astellas and Seagen Announce Chinas National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer (Business Wire)
Mar-06-23 12:29PM	Seagens Cancer Therapy Is Making It a Takeover Target (The Wall Street Journal)
08:00AM	Why Big Drugmakers Want to Buy Cancer Biotech Seagen (The Wall Street Journal)
Mar-05-23 06:00AM	The five-year returns have been impressive for Seagen (NASDAQ:SGEN) shareholders despite underlying losses increasing (Simply Wall St.)
Mar-01-23 07:00AM	Estimating The Fair Value Of Seagen Inc. (NASDAQ:SGEN) (Simply Wall St.)
Feb-28-23 12:40PM	Pfizer favored over Merck for Seagen acquisition: SVB analyst (Yahoo Finance)
Feb-27-23 07:04PM	Analyst Report: Seagen Inc. (Morningstar Research) +10.40%
12:03PM	Fisker, Zillow, Seagen, Union Pacific stocks rise after back-to-back losses for S&P 500 (Yahoo Finance Video)
11:37AM	Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 Billion (The Wall Street Journal)
11:15AM	Seagen Stock Jumps After Pfizer Deal Report (The Wall Street Journal)
10:20AM	Teslas Investor Day, Warren Buffetts letter to shareholders, Pfizer-Seagen deal: 3 things to know (Yahoo Finance Video)
09:28AM	Pfizer in talks to acquire biotech firm Seagen for $30 billion: Report (Yahoo Finance Video)
08:00AM	Seagen to Present at the Cowen 43rd Annual Health Care Conference (Business Wire)
03:13AM	Seagen, Union Pacific and Tesla rise premarket; Pfizer falls (Investing.com)
Feb-26-23 09:56PM	Pfizer in Early-Stage Talks to Acquire Seagen (The Wall Street Journal)
Feb-25-23 06:01AM	A Seagen Inc. (NASDAQ:SGEN) insider lowered their holding by 16% earlier this year (Simply Wall St.)
Feb-21-23 06:00AM	We're Not Worried About Seagen's (NASDAQ:SGEN) Cash Burn (Simply Wall St.)
Feb-17-23 05:40AM	Seagen Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Epstein David R	CEO	Nov 10	Sale	213.01	10,620	2,262,166	136,598	Nov 13 08:02 PM
HIMES VAUGHN B	Chief Technical Officer	Nov 09	Sale	213.32	8,785	1,874,053	42,574	Nov 13 07:32 PM
SIMPSON TODD E	Chief Financial Officer	Sep 21	Sale	206.50	80	16,520	128,723	Sep 22 07:45 PM
HIMES VAUGHN B	Chief Technical Officer	Sep 21	Sale	206.50	80	16,520	51,359	Sep 22 07:48 PM
DANSEY ROGER D	President, R&D & CMO	Sep 21	Sale	206.50	71	14,662	116,677	Sep 22 07:51 PM
LIU JEAN I	Chief Legal Officer	Sep 21	Sale	206.50	64	13,216	84,398	Sep 22 07:47 PM
ROMP CHARLES R	EVP, Commercial U.S.	Sep 21	Sale	206.50	45	9,292	69,111	Sep 22 07:46 PM
HIMES VAUGHN B	Chief Technical Officer	Sep 07	Option Exercise	44.09	8,785	387,331	60,224	Sep 08 05:09 PM
HIMES VAUGHN B	Chief Technical Officer	Sep 07	Sale	205.76	8,785	1,807,602	51,439	Sep 08 05:09 PM
DANSEY ROGER D	President, R&D & CMO	Aug 31	Sale	206.97	4,029	833,866	111,768	Sep 01 04:51 PM
SIMPSON TODD E	Chief Financial Officer	Aug 31	Sale	206.97	2,122	439,182	128,803	Sep 01 04:49 PM
LIU JEAN I	Chief Legal Officer	Aug 31	Sale	206.97	1,893	391,786	84,462	Sep 01 04:50 PM
HIMES VAUGHN B	Chief Technical Officer	Aug 31	Sale	206.97	1,795	371,504	51,439	Sep 01 04:51 PM
ROMP CHARLES R	EVP, Commercial U.S.	Aug 31	Sale	206.97	555	114,866	69,156	Sep 01 04:50 PM
DANSEY ROGER D	President, R&D & CMO	Aug 29	Sale	206.00	1,016	209,296	115,797	Aug 30 07:08 PM
SIMPSON TODD E	Chief Financial Officer	Aug 29	Sale	206.00	485	99,910	130,925	Aug 30 07:06 PM
ROMP CHARLES R	EVP, Commercial U.S.	Aug 29	Sale	206.00	438	90,228	69,711	Aug 30 07:06 PM
LIU JEAN I	Chief Legal Officer	Aug 29	Sale	206.00	405	83,430	86,355	Aug 30 07:04 PM
HIMES VAUGHN B	Chief Technical Officer	Aug 29	Sale	206.00	371	76,426	53,234	Aug 30 07:07 PM
WELCH DANIEL G	Director	Aug 28	Option Exercise	135.63	1,812	245,762	10,109	Aug 29 06:22 PM
WELCH DANIEL G	Director	Aug 28	Sale	209.08	3,315	693,094	6,794	Aug 29 06:22 PM
WELCH DANIEL G	Director	Aug 28	Sale	209.08	1,610	336,619	10,725	Aug 29 06:22 PM
ROMP CHARLES R	EVP, Commercial U.S.	Jul 03	Sale	192.46	708	136,262	59,069	Jul 05 08:18 PM
HIMES VAUGHN B	Chief Technical Officer	Jun 07	Option Exercise	41.04	16,215	665,464	60,052	Jun 09 06:50 PM
HIMES VAUGHN B	Chief Technical Officer	Jun 07	Sale	195.29	16,215	3,166,571	43,837	Jun 09 06:50 PM
ROMP CHARLES R	EVP, Commercial U.S.	May 16	Sale	189.86	349	66,261	59,777	May 18 07:04 PM
WELCH DANIEL G	Director	May 15	Option Exercise	135.63	1,864	252,814	8,117	May 16 07:23 PM
WELCH DANIEL G	Director	May 15	Sale	200.02	1,864	372,837	6,253	May 16 07:23 PM
WELCH DANIEL G	Director	May 02	Option Exercise	133.86	8,521	1,140,601	10,066	May 03 09:16 PM
WELCH DANIEL G	Director	May 02	Sale	200.07	8,872	1,775,024	6,253	May 03 09:16 PM
WELCH DANIEL G	Director	May 02	Sale	200.07	5,835	1,167,408	12,335	May 03 09:16 PM
BAKER BROS. ADVISORS LP	Director	May 01	Option Exercise	36.70	17,500	642,250	42,975,257	May 03 04:04 PM
WELCH DANIEL G	Director	May 01	Option Exercise	62.26	7,140	444,529	12,049	May 03 09:16 PM
WELCH DANIEL G	Director	May 01	Sale	200.06	7,435	1,487,462	6,604	May 03 09:16 PM
WELCH DANIEL G	Director	May 01	Sale	200.06	4,890	978,293	18,170	May 03 09:16 PM
DANSEY ROGER D	President, R&D & CMO	Apr 17	Option Exercise	72.64	10,000	726,400	109,389	Apr 19 06:14 PM
LIU JEAN I	Chief Legal Officer	Apr 17	Option Exercise	39.15	5,000	195,750	91,763	Apr 19 06:16 PM
DANSEY ROGER D	President, R&D & CMO	Apr 17	Sale	205.95	10,000	2,059,488	99,389	Apr 19 06:14 PM
LIU JEAN I	Chief Legal Officer	Apr 17	Sale	205.86	5,000	1,029,310	86,763	Apr 19 06:16 PM
SIMPSON TODD E	Chief Financial Officer	Apr 10	Option Exercise	46.37	55,344	2,566,301	159,310	Apr 12 07:50 PM
SIMPSON TODD E	Chief Financial Officer	Apr 10	Sale	204.58	55,344	11,322,143	118,946	Apr 12 07:50 PM
DANSEY ROGER D	President, R&D & CMO	Apr 06	Sale	205.86	333	68,550	99,389	Apr 07 07:28 PM
HIMES VAUGHN B	Chief Technical Officer	Apr 06	Sale	205.86	243	50,023	68,837	Apr 07 07:29 PM
SIMPSON TODD E	Chief Financial Officer	Apr 06	Sale	205.86	243	50,023	118,946	Apr 07 07:40 PM
LIU JEAN I	Chief Legal Officer	Apr 06	Sale	205.86	174	35,819	86,763	Apr 07 07:36 PM
ROMP CHARLES R	EVP, Commercial U.S.	Apr 06	Sale	205.86	133	27,379	60,126	Apr 07 07:38 PM
WELCH DANIEL G	Director	Apr 03	Option Exercise	60.94	17,525	1,068,060	14,057	Apr 05 09:07 PM
WELCH DANIEL G	Director	Apr 03	Sale	201.61	20,275	4,087,548	4,149	Apr 05 09:07 PM
WELCH DANIEL G	Director	Apr 03	Sale	201.61	10,725	2,162,296	12,335	Apr 05 09:07 PM
LIU JEAN I	Chief Legal Officer	Mar 16	Option Exercise	39.15	5,000	195,750	90,113	Mar 17 04:57 PM
LIU JEAN I	Chief Legal Officer	Mar 16	Sale	199.90	5,000	999,500	85,113	Mar 17 04:57 PM
DANSEY ROGER D	President, R&D & CMO	Mar 15	Option Exercise	72.64	10,000	726,400	106,853	Mar 17 04:20 PM
WELCH DANIEL G	Director	Mar 15	Option Exercise	38.82	2,037	79,076	9,256	Mar 17 04:43 PM
DANSEY ROGER D	President, R&D & CMO	Mar 15	Sale	199.81	10,000	1,998,115	96,853	Mar 17 04:20 PM
WELCH DANIEL G	Director	Mar 15	Sale	200.05	2,357	471,518	6,899	Mar 17 04:43 PM
WELCH DANIEL G	Director	Mar 15	Sale	200.05	1,246	249,262	23,060	Mar 17 04:43 PM
WELCH DANIEL G	Director	Mar 14	Option Exercise	38.82	470	18,245	13,447	Mar 16 06:05 AM
WELCH DANIEL G	Director	Mar 14	Sale	200.00	544	108,800	12,977	Mar 16 06:05 AM
WELCH DANIEL G	Director	Mar 14	Sale	200.00	288	57,600	24,306	Mar 16 06:05 AM
WELCH DANIEL G	Director	Mar 13	Option Exercise	39.51	15,018	593,370	23,036	Mar 16 06:05 AM
WELCH DANIEL G	Director	Mar 13	Sale	200.36	17,374	3,481,015	7,219	Mar 16 06:05 AM
WELCH DANIEL G	Director	Mar 13	Sale	200.36	9,191	1,841,487	24,594	Mar 16 06:05 AM
SIMPSON TODD E	Chief Financial Officer	Mar 09	Option Exercise	45.30	42,793	1,938,523	159,978	Mar 10 04:11 PM
SIMPSON TODD E	Chief Financial Officer	Mar 09	Sale	176.61	42,793	7,557,550	117,185	Mar 10 04:11 PM
HIMES VAUGHN B	Chief Technical Officer	Mar 02	Option Exercise	41.04	16,215	665,464	80,781	Mar 03 05:36 PM
HIMES VAUGHN B	Chief Technical Officer	Mar 02	Sale	177.21	16,215	2,873,477	67,257	Mar 03 05:36 PM
SIMPSON TODD E	Chief Financial Officer	Feb 27	Sale	182.53	20,000	3,650,600	117,185	Feb 28 07:24 PM
SIMPSON TODD E	Chief Financial Officer	Feb 16	Option Exercise	39.15	39,946	1,563,886	177,131	Feb 21 07:35 PM
LIU JEAN I	Chief Legal Officer	Feb 16	Option Exercise	39.15	5,000	195,750	90,113	Feb 21 07:33 PM
SIMPSON TODD E	Chief Financial Officer	Feb 16	Sale	160.00	39,946	6,391,400	137,185	Feb 21 07:35 PM
LIU JEAN I	Chief Legal Officer	Feb 16	Sale	155.00	5,000	775,000	85,113	Feb 21 07:33 PM
DANSEY ROGER D	President, R&D & CMO	Feb 15	Option Exercise	72.64	10,000	726,400	106,853	Feb 17 04:23 PM
DANSEY ROGER D	President, R&D & CMO	Feb 15	Sale	140.64	10,000	1,406,395	96,853	Feb 17 04:23 PM
GRYSKA DAVID W	Director	Feb 13	Option Exercise	36.70	8,750	321,125	49,003	Feb 15 06:33 PM
DANSEY ROGER D	President, R&D & CMO	Feb 02	Sale	138.52	783	108,461	96,853	Feb 03 08:01 PM
DANSEY ROGER D	President, R&D & CMO	Jan 24	Option Exercise	72.64	10,000	726,400	107,539	Jan 26 07:41 PM
LIU JEAN I	Chief Legal Officer	Jan 24	Option Exercise	39.15	5,000	195,750	90,113	Jan 26 07:39 PM
DANSEY ROGER D	President, R&D & CMO	Jan 24	Sale	135.00	10,000	1,350,000	97,539	Jan 26 07:41 PM
LIU JEAN I	Chief Legal Officer	Jan 24	Sale	135.03	5,000	675,134	85,113	Jan 26 07:39 PM
LIU JEAN I	Chief Legal Officer	Jan 17	Sale	130.71	578	75,548	85,113	Jan 19 07:16 PM
DANSEY ROGER D	President R&D & CMO	Jan 05	Option Exercise	72.64	7,500	544,800	105,039	Jan 06 07:10 PM
LIU JEAN I	Chief Legal Officer	Jan 05	Option Exercise	39.15	4,525	177,154	90,216	Jan 06 07:08 PM
DANSEY ROGER D	President R&D & CMO	Jan 05	Sale	135.00	7,500	1,012,500	97,539	Jan 06 07:10 PM
LIU JEAN I	Chief Legal Officer	Jan 05	Sale	135.00	4,525	610,875	85,691	Jan 06 07:08 PM
DANSEY ROGER D	President R&D & CMO	Jan 04	Option Exercise	72.64	2,500	181,600	100,039	Jan 06 07:10 PM
LIU JEAN I	Chief Legal Officer	Jan 04	Option Exercise	39.15	475	18,596	86,166	Jan 06 07:08 PM
DANSEY ROGER D	President R&D & CMO	Jan 04	Sale	135.00	2,500	337,500	97,539	Jan 06 07:10 PM
LIU JEAN I	Chief Legal Officer	Jan 04	Sale	135.00	475	64,125	85,691	Jan 06 07:08 PM
ROMP CHARLES R	EVP, Commercial U.S.	Dec 20	Sale	127.63	1,129	144,094	58,475	Dec 21 06:48 PM
DANSEY ROGER D	President, Research and Develo	Dec 14	Option Exercise	77.16	10,000	771,628	106,942	Dec 16 07:42 PM
DANSEY ROGER D	President, Research and Develo	Dec 14	Sale	135.00	10,000	1,350,000	97,539	Dec 16 07:42 PM
Simonian Nancy A	Director	Dec 12	Option Exercise	36.70	8,750	321,125	62,753	Dec 14 05:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGEN

Seagen Inc

Upgrade your FINVIZ experience